Annual report pursuant to Section 13 and 15(d)

Supplemental Balance Sheet and Cash Flow Information (Tables)

v3.23.2
Supplemental Balance Sheet and Cash Flow Information (Tables)
12 Months Ended
Jun. 30, 2023
Notes Tables  
Schedule of inventories

Inventories consist of (in thousands):

    

June 30, 

    

2023

    

2022

Raw materials

$

84,551

$

79,291

Finished goods(1)

 

92,474

 

66,943

Inventories, net

$

177,025

$

146,234

(1) Finished goods inventory of $5,387 and $5,111 is included within other assets in the June 30, 2023 and June 30, 2022 Balance Sheets, respectively, as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.
Schedule of property and equipment

Property and equipment consist of (in thousands):

June 30, 

2023

    

2022

Land

$

9,100

$

8,572

Buildings and improvements

 

245,302

 

229,551

Machinery and equipment

190,019

 

174,813

Construction in progress

 

15,491

21,729

Property and equipment, cost

 

459,912

 

434,665

Accumulated depreciation and amortization

 

(233,712)

 

(211,423)

Property and equipment, net

$

226,200

$

223,242

Schedule of intangible assets

Intangibles assets were comprised of the following (in thousands):

Useful Life

June 30, 

(years)

2023

2022

Developed technology

 

9 - 15

$

616,311

$

542,038

Trade names

 

2 - 20

 

146,945

 

146,457

Customer relationships

 

7 - 16

 

213,878

 

225,882

Patents

 

10

 

3,815

 

3,313

Other intangibles

 

5 - 15

 

11,566

 

6,306

Definite-lived intangible assets

 

992,515

 

923,996

Accumulated amortization

 

(480,570)

 

(415,174)

Definite-lived intangibles assets, net

 

511,945

 

508,822

In process research and development

 

22,700

 

22,700

Total intangible assets, net

$

534,645

$

531,522

Schedule of changes in carrying amount of net intangible assets

Changes to the carrying amount of net intangible assets consist of (in thousands):

    

June 30, 

2023

2022

Beginning balance

$

531,522

$

615,968

Acquisitions

 

75,600

 

Other additions(1)

 

5,710

 

293

Amortization expense

 

(77,491)

 

(74,147)

Currency translation

(696)

(2,029)

Eminence impairment

(8,563)

Ending balance

$

534,645

$

531,522

Schedule of estimated future amortization expense for intangible assets

The estimated future amortization expense for intangible assets as of June 30, 2023, excluding any possible future amortization associated with acquired in-process research and development (IPR&D) which has not met technological feasibility, is as follows (in thousands):

2024

    

$

75,331

2025

 

72,056

2026

 

68,089

2027

 

57,920

2028

 

54,470

Thereafter

 

184,079

Total

$

511,945

Schedule of changes to the carrying amount of goodwill

Changes in goodwill by segment and in total consist of (in thousands):

    

    

Diagnostics and

    

Protein Sciences

 Genomics

Total

June 30, 2021

    

$

392,717

$

450,350

$

843,067

Acquisitions

 

(4,407)

 

(4,407)

Eminence impairment

(8,275)

(8,275)

Currency translation

 

(7,949)

(335)

 

(8,284)

June 30, 2022

$

376,493

$

445,608

$

822,101

Acquisitions

 

51,257

51,257

Currency translation

 

(723)

102

(621)

June 30, 2023

$

427,027

$

445,710

$

872,737

Schedule of other assets

Other assets consist of (in thousands):

    

June 30, 

    

2023

2022

Investment in Wilson Wolf

$

255,857

$

25,000

Derivative instruments

16,857

11,026

Long-term inventory

5,387

5,111

Other

 

7,201

 

5,691

Other assets

$

285,302

$

46,828

Schedule of supplemental cash flow information

Supplemental cash flow information was as follows (in thousands):

    

Year Ended June 30, 

    

2023

    

2022

    

2021

Income taxes paid

$

88,428

$

30,341

$

20,952

Interest paid

 

8,368

 

11,027

 

13,576

Non-cash activities:

 

 

  

 

  

Acquisition-related liabilities (1)

 

12,100

 

20,400

 

23,600

Other intangibles (2)

 

 

 

4,000

(1) Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5.
(2) $4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021.